封面
市场调查报告书
商品编码
1405766

药品市场规模/份额/趋势分析报告:依分子类型、产品、类型、疾病、剂型、年龄层、给药途径、终端市场、区域、细分趋势:2023-2030

Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Formulation, By Age Group, By Route Of Administration, By End Market, By Region, And Segment Forecasts, 2023 - 2030

出版日期: | 出版商: Grand View Research | 英文 250 Pages | 商品交期: 2-10个工作天内

价格

医药市场的成长与趋势:

Grand View Research, Inc.最新报告显示,预计2023年至2030年全球医药市场规模将以6.12%的复合年增长率成长,2030年将达到23,632.5亿美元。

慢性病盛行率的增加以及开发新疗法的需求不断增长推动了药品市场的成长。根据国家老化委员会估计,约 95% 的老年人口至少患有一种慢性病,约 80% 的老年人口患有两种或两种以上慢性病。此外,糖尿病、关节炎和心臟病等慢性疾病对老年人口的影响尤其严重。

认识是预防、早期发现、集中治疗和有效治疗的关键。了解疾病及其症状的人更有可能采取预防措施,例如检查、测试和健康检查。对各种疾病的认识不断提高也是製药业的驱动因素。随着人们对癌症和糖尿病等疾病的认识越来越多,如果患上这些疾病,他们更有可能寻求治疗。公共机构和私人组织正在采取各种措施来传播意识和教育公众。此外,越来越多的人购买保险来支付处方药费用,导致药品需求增加。

此外,新型疗法开发的技术进步显着增加了全球对药品的需求。製药业不仅在研发方面,而且在产品销售和分销方面都以前所未有的速度进行投资。该行业专注于明确、直接地解决人们的健康问题。製药业对于患者护理和社区发展至关重要,提供许多挽救生命的治疗方法、创造就业机会并为全球经济做出贡献。

许多生物製药,包括细菌和病毒,用于疫苗生产、发酵过程和生物技术。该市场由各种各样的公司组成,包括大型製药公司、中型专业製药公司、虚拟药物公司、非专利製造商以及小型生物技术和生物製药公司。此外,参与各种治疗产品开发和配製的主要参与者都专注于联合研究和联盟,以开发新药并保持市场竞争力。

此外,多家公司正在努力开发新药,以满足预防和治疗这种疾病不断增长的需求。例如,2023年4月,罗氏公司宣布其湿性老龄化黄斑部病变治疗药物Vabysmo于2022年1月获得FDA核准,2023年第一季销售额约为5亿日元。美元销售额。该药销售额年增超过500%,超过了多发性硬化症药物Ocrevus和血友病药物Hemlibra等竞争药物。此外,2023年7月,诺华公司获得美国FDA核准扩大Rexvio(通用名:inclisiran)适应症,用于治疗高LDL-C水平且心臟病高风险患者。

医药市场报告亮点

  • 从分子类型来看,传统药物(小分子)主导整个市场。传统药物在医药市场上的优越性归因于成熟的製造流程、可预测的药物动力学和口服生物利用度。
  • 从产品来看,2022年,品牌药在医药市场中占据最大的销售份额,因为专门从事品牌药的大型製药公司在市场上已经存在很长时间了。
  • 按类型划分,成药预计在预测期内将呈现最快的成长速度,因为看医生的需求减少,透过该管道更容易采购药品。正是因为如此。
  • 依疾病分类,癌症在 2022 年占据医药市场的主导地位。癌症领域在市场上的主导地位是由全球不同类型癌症盛行率不断上升、对创新和有效治疗方法的需求不断增加以及该领域的大规模投资和研究推动的,这可归因于几个主要因素。
  • 以剂型划分,2022年锭剂占据医药市场最大销售份额。
  • 从给药途径来看,2022年口服给药领域在全球市场占据主导地位。
  • 按年龄组别划分,预计成人群体在预测期内将显示出最快的增长,因为成年人口在全球消费各种药物的患者群占主导地位。
  • 在终端市场方面,由于高龄化、慢性病数量增加以及治疗方法的进步,医疗保健需求不断增加,医院在製药业占据主导地位。
  • 由于该地区医疗基础设施发达、慢性病病例数量不断增加、多个主要参与者的存在以及足够的市场份额,北美在 2022 年占据了最大的销售份额,部分原因是创新药物的供应。

目录

第一章 医药市场:调查方法与范围

第二章医药市场:执行摘要

  • 市场概述
  • 分段简介
  • 竞争形势概览

第三章医药市场变数、趋势和范围

  • 市场区隔和范围
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 波特五力分析
  • PESTLE分析

第四章 医药市场:分子型前景预测及趋势分析

  • 分子型展望:变异分析
  • 生技药品和生物相似药(大分子)
    • 2018-2030 年生技药品和生物相似药市场估计和预测
  • 常规药物(小分子)
    • 2018-2030 年传统药物市场估计与预测

第五章医药市场:产品评估/趋势分析

  • 医药市场:产品波动分析
  • 品牌
    • 2018-2030 年品牌产品市场收益估计与预测
  • 非专利的
    • 2018-2030 年非专利产品市场收益估计与预测

第六章医药市场:类型估计与趋势分析

  • 医药市场:类型变异分析
  • 处方笺
    • 2018-2030 年处方笺市场收益估计与预测
  • OTC
    • 2018-2030 年场外交易市场收益估算与预测

第七章 医药市场:疾病前景预测与趋势分析

  • 医药市场:疾病前景变化分析
  • 心血管疾病
    • 2018-2030 年心血管疾病市场收益估计与预测
  • 癌症
    • 2018-2030年癌症市场收益估算与预测
  • 糖尿病
    • 2018-2030 年糖尿病市场收益估算与预测
  • 感染疾病
    • 2018-2030年感染疾病市场收益估计与预测
  • 神经系统疾病
    • 2018-2030年神经系统疾病市场收益估计与预测
  • 呼吸系统疾病
    • 2018-2030 年呼吸系统疾病市场收益估计与预测
  • 自体免疫疾病
    • 2018-2030 年自体自体免疫疾病市场收益估计与预测
  • 心理健康障碍
    • 2018-2030 年精神健康障碍市场收益估计与预测
  • 胃肠道疾病
    • 2018-2030年胃肠道疾病市场收益估计与预测
  • 女性健康疾病
    • 2018-2030 年女性健康疾病市场收益估计与预测
  • 遗传和罕见遗传疾病
    • 遗传疾病和罕见遗传疾病市场收益估计和预测,2018-2030年
  • 皮肤病
    • 2018-2030年皮肤病市场收益估计与预测
  • 肥胖
    • 2018-2030 年肥胖市场收益估算与预测
  • 肾臟疾病
    • 2018-2030 年肾臟疾病市场收益估计与预测
  • 肝病
    • 2018-2030年肝病市场收益估算与预测
  • 血液疾病
    • 2018-2030 年血液疾病市场收益估计与预测
  • 眼睛状况
    • 2018-2030 年眼部疾病市场收益估计与预测
  • 不孕症
    • 2018-2030年不孕症市场收益估算与预测
  • 内分泌疾病
    • 2018-2030年内分泌疾病市场收益估计与预测
  • 过敏
    • 2018-2030年过敏市场收益估计与预测
  • 其他的
    • 2018-2030 年其他市场收益估计与预测

第八章医药市场:给药途径预估及趋势分析

  • 医药市场:给药途径变化分析
  • 口服
    • 2018-2030年口腔市场收益估计与预测
  • 局部的
    • 局部市场收益预估及2018-2030年
  • 胃肠外的
    • 2018-2030 年註射剂市场收益估计与预测
  • 吸入
    • 2018-2030年吸入剂市场收益估计与预测
  • 其他的
    • 2018-2030 年其他市场收益估计与预测

第九章医药市场:剂型预估及趋势分析

  • 医药市场:剂型变异分析
  • 药片
    • 2018-2030年平板电脑市场收益估算与预测
  • 胶囊
    • 胶囊市场收益预测及2018-2030年
  • 注射
    • 2018-2030年註射剂市场收益估算与预测
    • 2018-2030年喷雾市场收益估算与预测
  • 暂停
    • 2018-2030年悬吊市场收益估算与预测
  • 粉末
    • 2018-2030年粉末市场收益估计与预测
  • 其他处方
    • 2018-2030 年其他药品市场收益估计与预测

第十章医药市场:年龄组别估计及趋势分析

  • 医药市场:年龄层变化分析
  • 儿童/青少年
    • 2018-2030 年儿童和青少年市场收益估算和预测
  • 成人
    • 2018-2030 年成人市场收益估算与预测
  • 老年人
    • 2018-2030 年老年市场收益估算与预测

第十一章医药市场:最终市场预测与趋势分析

  • 医药市场:最终市场波动分析
  • 医院
    • 2018-2030年医院市场收益估算与预测
  • 诊所
    • 2018-2030年诊所市场收益估算与预测
  • 其他的
    • 2018-2030 年其他市场收益估计与预测

第十二章医药市场:区域业务分析

  • 2022 年及 2030 年按地区市场占有率
  • 北美洲
    • 北美医药市场,2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲医药市场,2018-2030
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太医药市场,2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲医药市场,2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 中东和非洲医药市场,2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十三章竞争形势

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2022年主要企业市场占有率分析
  • 企业热力图分析
  • 公司简介
    • F. HOFFMANN-LA ROCHE LTD.
    • NOVARTIS AG
    • ABBVIE INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • MERCK &CO., INC.
    • PFIZER INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • SANOFI
    • GSK PLC
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
Product Code: GVR-4-68040-159-7

Pharmaceutical Market Growth & Trends:

The global pharmaceutical market size is expected to reach USD 2,363.25 billion by 2030, expandingat a CAGR of 6.12% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023 , F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022 , brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights:

  • Based on molecule type, conventional drugs (small molecules) dominated the overall market. Conventional drugs' dominance in the pharmaceuticals market is due to their well-established manufacturing processes, predictable pharmacokinetics, and oral bioavailability
  • Based on product, the branded segment held the largest revenue share in the pharmaceuticals market in 2022, owing to the presence of several giant pharmaceutical players in the market specializing in branded medication since a long time
  • Based on type, OTC pharmaceuticals are expected to showcase the fastest growth rate over the forecast period owing to the ease of procurement of medication through this channel aided by the reduced need to visit a physician
  • In terms of disease, cancer dominated the pharmaceuticals market in 2022. The dominance of the cancer segment in the market can be attributed to several key factors such as the rising global incidence of various types of cancer, increased demand for innovative & effective treatments, and significant investments and research in this area
  • On the basis of formulation, tablets held the largest revenue share in the pharmaceuticals market in 2022, owing to the ease of administration and greater adoption of this formulation
  • In terms of route of administration, the oral route of administration segment dominated the global market in 2022
  • Based on age group, the adult segment is expected to show fastest growth over the forecast period, owing to the dominance of the adult population globally in the patient pool that consumes various pharmaceuticals
  • In terms of the end market, hospitals dominated the pharmaceuticals industry, underscored by the escalating healthcare demands due to an aging population, increased prevalence of chronic illnesses, and advancements in medical treatments
  • North America held the largest revenue share in 2022, which can be attributed to the developed regional healthcare infrastructure, growing cases of chronic diseases, presence of several key players, and availability of proper and innovative medications in the region

Table of Contents

Chapter 1. Pharmaceutical Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Pharmaceutical Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing healthcare spending by the government
      • 3.2.1.2. Improving affordability driven by rising per capita income
      • 3.2.1.3. Increasing awareness about healthcare among the population
      • 3.2.1.4. Increasing access to innovative and modern medicines
      • 3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
      • 3.2.1.6. Rising chronic diseases and geriatric population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. COVID - 19 pandemic
      • 3.2.2.2. Intensification of competition from generic and biosimilar drugs
      • 3.2.2.3. Increasing price - sensitivity of customers for non - reimbursed drugs
      • 3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
  • 3.3. Porter's Five Forces Analysis
  • 3.4. PESTLE Analysis

Chapter 4. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis

  • 4.1. Molecule Type Outlook: Movement Analysis
  • 4.2. Biologics & Biosimilars (Large Molecules)
    • 4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.1.1 Monoclonal Antibodies
      • 4.2.1.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.2.3 Vaccines
      • 4.2.2.4 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.3.5 Cell & Gene Therapy
      • 4.2.3.6 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.4.7 Others
      • 4.2.4.8 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3. Conventional Drugs (Small Molecules)
    • 4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Pharmaceutical Market: Product Estimates & Trend Analysis

  • 5.1. Pharmaceutical Market: Product Movement Analysis
  • 5.2. Branded
    • 5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Generic
    • 5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Pharmaceutical Market: Type Estimates & Trend Analysis

  • 6.1. Pharmaceutical Market: Type Movement Analysis
  • 6.2. Prescription
    • 6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3. OTC
    • 6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Pharmaceutical Market: Diseases Outlook Estimates & Trend Analysis

  • 7.1. Pharmaceutical Market: Diseases Outlook Movement Analysis
  • 7.2. Cardiovascular diseases
    • 7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Cancer
    • 7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Diabetes
    • 7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Infectious diseases
    • 7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Neurological disorders
    • 7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Respiratory diseases
    • 7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. Autoimmune diseases
    • 7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.9. Mental health disorders
    • 7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.10. Gastrointestinal disorders
    • 7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.11. Women's Health Diseases
    • 7.11.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.12. Genetic and Rare genetic diseases
    • 7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.13. Dermatological conditions
    • 7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.14. Obesity
    • 7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.15. Renal diseases
    • 7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.17. Liver conditions
    • 7.17.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.17. Hematological disorders
    • 7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.18. Eye conditions
    • 7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.19. Infertility conditions
    • 7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.20. Endocrine disorders
    • 7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.21. Allergies
    • 7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.22. Others
    • 7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Pharmaceutical Market: Route of Administration Movement Analysis
  • 8.2. Oral
    • 8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Topical
    • 8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Parenteral
    • 8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 8.4.1.1. Intravenous
      • 8.4.1.2. Intramuscular
  • 8.5. Inhalations
    • 8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Other
    • 8.6.1. Other Routes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Pharmaceutical Market: Formulation Estimates & Trend Analysis

  • 9.1. Pharmaceutical Market: Formulation Movement Analysis
  • 9.2. Tablets
    • 9.2.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3. Capsules
    • 9.3.1. Capsules Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4. Injectable
    • 9.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5. Sprays
    • 9.5.1. Sprays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.6. Suspensions
    • 9.6.1. Suspensions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7. Powders
    • 9.7.1. Powders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8. Other Formulations
    • 9.8.1. Other Formulations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 10.1. Pharmaceutical Market: Age Group Movement Analysis
  • 10.2. Children & Adolescents
    • 10.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.3. Adults
    • 10.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.4. Geriatric
    • 10.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Pharmaceutical Market: End Market Estimates & Trend Analysis

  • 11.1. Pharmaceutical Market: End Market Movement Analysis
  • 11.2. Hospitals
    • 11.2.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 11.3. Clinics
    • 11.3.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 11.4. Others
    • 11.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 12. Pharmaceutical Market: Regional Business Analysis

  • 12.1. Pharmaceutical Market Share By Region, 2022 & 2030
  • 12.2. North America
    • 12.2.1. North America Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.2.2. U.S.
      • 12.2.2.1. Key Country Dynamics
      • 12.2.2.2. Target Disease Prevalence
      • 12.2.2.3. Competitive Scenario
      • 12.2.2.4. Regulatory Framework
      • 12.2.2.5. Reimbursement Scenario
      • 12.2.2.6. U.S. Pharmaceutical market, 2018 - 2030 (USD MILLION)
    • 12.2.3. Canada
      • 12.2.3.1. Key Country Dynamics
      • 12.2.3.2. Target Disease Prevalence
      • 12.2.3.3. Competitive Scenario
      • 12.2.3.4. Regulatory Framework
      • 12.2.3.5. Reimbursement Scenario
      • 12.2.3.6. Canada Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.3. Europe
    • 12.3.1. Europe Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.2. Germany
      • 12.3.2.1. Key Country Dynamics
      • 12.3.2.2. Target Disease Prevalence
      • 12.3.2.3. Competitive Scenario
      • 12.3.2.4. Regulatory Framework
      • 12.3.2.5. Reimbursement Scenario
      • 12.3.2.6. Germany Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.3. UK
      • 12.3.3.1. Key Country Dynamics
      • 12.3.3.2. Target Disease Prevalence
      • 12.3.3.3. Competitive Scenario
      • 12.3.3.4. Regulatory Framework
      • 12.3.3.5. Reimbursement Scenario
      • 12.3.3.6. UK Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.4. France
      • 12.3.4.1. Key Country Dynamics
      • 12.3.4.2. Target Disease Prevalence
      • 12.3.4.3. Competitive Scenario
      • 12.3.4.4. Regulatory Framework
      • 12.3.4.5. Reimbursement Scenario
      • 12.3.4.6. France Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.5. Italy
      • 12.3.5.1. Key Country Dynamics
      • 12.3.5.2. Target Disease Prevalence
      • 12.3.5.3. Competitive Scenario
      • 12.3.5.4. Regulatory Framework
      • 12.3.5.5. Reimbursement Scenario
      • 12.3.5.6. Italy Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.6. Spain
      • 12.3.6.1. Key Country Dynamics
      • 12.3.6.2. Target Disease Prevalence
      • 12.3.6.3. Competitive Scenario
      • 12.3.6.4. Regulatory Framework
      • 12.3.6.5. Reimbursement Scenario
      • 12.3.6.6. Spain Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.7. Denmark
      • 12.3.12.1. Key Country Dynamics
      • 12.3.12.2. Target Disease Prevalence
      • 12.3.12.3. Competitive Scenario
      • 12.3.12.4. Regulatory Framework
      • 12.3.12.5. Reimbursement Scenario
      • 12.3.12.6. Denmark Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.8. Sweden
      • 12.3.8.1. Key Country Dynamics
      • 12.3.8.2. Target Disease Prevalence
      • 12.3.8.3. Competitive Scenario
      • 12.3.8.4. Regulatory Framework
      • 12.3.8.5. Reimbursement Scenario
      • 12.3.8.6. Sweden Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.3.9. Norway
      • 12.3.9.1. Key Country Dynamics
      • 12.3.9.2. Target Disease Prevalence
      • 12.3.9.3. Competitive Scenario
      • 12.3.9.4. Regulatory Framework
      • 12.3.9.5. Reimbursement Scenario
      • 12.3.9.6. Norway Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.4. Asia Pacific
    • 12.4.1. Asia Pacific Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.4.2. Japan
      • 12.4.2.1. Key Country Dynamics
      • 12.4.2.2. Target Disease Prevalence
      • 12.4.2.3. Competitive Scenario
      • 12.4.2.4. Regulatory Framework
      • 12.4.2.5. Reimbursement Scenario
      • 12.4.2.6. Japan Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.4.3. China
      • 12.4.3.1. Key Country Dynamics
      • 12.4.3.2. Target Disease Prevalence
      • 12.4.3.3. Competitive Scenario
      • 12.4.3.4. Regulatory Framework
      • 12.4.3.5. Reimbursement Scenario
      • 12.4.3.6. China Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.4.4. India
      • 12.4.4.1. Key Country Dynamics
      • 12.4.4.2. Target Disease Prevalence
      • 12.4.4.3. Competitive Scenario
      • 12.4.4.4. Regulatory Framework
      • 12.4.4.5. Reimbursement Scenario
      • 12.4.4.6. India Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.4.5. South Korea
      • 12.4.5.1. Key Country Dynamics
      • 12.4.5.2. Target Disease Prevalence
      • 12.4.5.3. Competitive Scenario
      • 12.4.5.4. Regulatory Framework
      • 12.4.5.5. Reimbursement Scenario
      • 12.4.5.6. South Korea Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.4.6. Australia
      • 12.4.6.1. Key Country Dynamics
      • 12.4.6.2. Target Disease Prevalence
      • 12.4.6.3. Competitive Scenario
      • 12.4.6.4. Regulatory Framework
      • 12.4.6.5. Reimbursement Scenario
      • 12.4.6.6. Australia Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.4.7. Thailand
      • 12.4.7.1. Key Country Dynamics
      • 12.4.7.2. Target Disease Prevalence
      • 12.4.7.3. Competitive Scenario
      • 12.4.7.4. Regulatory Framework
      • 12.4.7.5. Reimbursement Scenario
      • 12.4.7.6. Thailand Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.5. Latin America
    • 12.5.1. Latin America Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.5.2. Brazil
      • 12.5.2.1. Key Country Dynamics
      • 12.5.2.2. Target Disease Prevalence
      • 12.5.2.3. Competitive Scenario
      • 12.5.2.4. Regulatory Framework
      • 12.5.2.5. Reimbursement Scenario
      • 12.5.2.6. Brazil Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.5.3. Mexico
      • 12.5.3.1. Key Country Dynamics
      • 12.5.3.2. Target Disease Prevalence
      • 12.5.3.3. Competitive Scenario
      • 12.5.3.4. Regulatory Framework
      • 12.5.3.5. Reimbursement Scenario
      • 12.5.3.6. Mexico Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.5.4. Argentina
      • 12.5.4.1. Key Country Dynamics
      • 12.5.4.2. Target Disease Prevalence
      • 12.5.4.3. Competitive Scenario
      • 12.5.4.4. Regulatory Framework
      • 12.5.4.5. Reimbursement Scenario
      • 12.5.4.6. Argentina Pharmaceutical market, 2018 - 2030 (USD Million)
  • 12.6. MEA
    • 12.6.1. MEA Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.6.2. South Africa
      • 12.6.2.1. Key Country Dynamics
      • 12.6.2.2. Target Disease Prevalence
      • 12.6.2.3. Competitive Scenario
      • 12.6.2.4. Regulatory Framework
      • 12.6.2.5. Reimbursement Scenario
      • 12.6.2.6. South Africa Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.6.3. Saudi Arabia
      • 12.6.3.1. Key Country Dynamics
      • 12.6.3.2. Target Disease Prevalence
      • 12.6.3.3. Competitive Scenario
      • 12.6.3.4. Regulatory Framework
      • 12.6.3.5. Reimbursement Scenario
      • 12.6.3.6. Saudi Arabia Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.6.4. UAE
      • 12.6.4.1. Key Country Dynamics
      • 12.6.4.2. Target Disease Prevalence
      • 12.6.4.3. Competitive Scenario
      • 12.6.4.4. Regulatory Framework
      • 12.6.4.5. Reimbursement Scenario
      • 12.6.4.6. UAE Pharmaceutical market, 2018 - 2030 (USD Million)
    • 12.6.5. Kuwait
      • 12.6.5.1. Key Country Dynamics
      • 12.6.5.2. Target Disease Prevalence
      • 12.6.5.3. Competitive Scenario
      • 12.6.5.4. Regulatory Framework
      • 12.6.5.5. Reimbursement Scenario
      • 12.6.5.6. Kuwait Pharmaceutical market, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

  • 13.1. Company Categorization
  • 13.2. Strategy Mapping
    • 13.2.1. New Product Launch
    • 13.2.2. Partnerships
    • 13.2.3. Acquisition
    • 13.2.4. Collaboration
    • 13.2.5. Funding
  • 13.3. Key Company Market Share Analysis, 2022
  • 13.4. Company Heat Map Analysis
  • 13.5. Company Profiles
    • 13.5.1. F. HOFFMANN - LA ROCHE LTD.
      • 13.5.1.1. Company Overview
      • 13.5.1.2. Financial Performance
      • 13.5.1.3. Product Benchmarking
      • 13.5.1.4. Strategic Initiatives
    • 13.5.2. NOVARTIS AG
      • 13.5.2.1. Company Overview
      • 13.5.2.2. Financial Performance
      • 13.5.2.3. Product Benchmarking
      • 13.5.2.4. Strategic Initiatives
    • 13.5.3. ABBVIE INC.
      • 13.5.3.1. Company Overview
      • 13.5.3.2. Financial Performance
      • 13.5.3.3. Product Benchmarking
      • 13.5.3.4. Strategic Initiatives
    • 13.5.4. JOHNSON & JOHNSON SERVICES, INC.
      • 13.5.4.1. Company Overview
      • 13.5.4.2. Financial Performance
      • 13.5.4.3. Product Benchmarking
      • 13.5.4.13. Strategic Initiatives
    • 13.5.5. MERCK & CO., INC.
      • 13.5.5.1. Company Overview
      • 13.5.5.2. Financial Performance
      • 13.5.5.3. Product Benchmarking
      • 13.5.5.4. Strategic Initiatives
    • 13.5.6. PFIZER INC.
      • 13.5.6.1. Company Overview
      • 13.5.6.2. Financial Performance
      • 13.5.6.3. Product Benchmarking
      • 13.5.6.4. Strategic Initiatives
    • 13.5.7. BRISTOL - MYERS SQUIBB COMPANY
      • 13.5.7.1. Company Overview
      • 13.5.7.2. Financial Performance
      • 13.5.7.3. Product Benchmarking
      • 13.5.7.4. Strategic Initiatives
    • 13.5.8. SANOFI
      • 13.5.8.1. Company Overview
      • 13.5.8.2. Financial Performance
      • 13.5.8.3. Product Benchmarking
      • 13.5.8.4. Strategic Initiatives
    • 13.5.9. GSK PLC
      • 13.5.9.1. Company Overview
      • 13.5.9.2. Financial Performance
      • 13.5.9.3. Product Benchmarking
      • 13.5.9.4. Strategic Initiatives
    • 13.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 13.5.10.1. Company Overview
      • 13.5.10.2. Financial Performance
      • 13.5.10.3. Product Benchmarking
      • 13.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 4 Global Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 5 Global Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 Global Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 7 Global Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 8 Global Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 9 Global Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 10 Global Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 11 North America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 12 North America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 13 North America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 14 North America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 15 North America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 16 North America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 17 North America Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 18 North America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 19 North America Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 24 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 25 U.S. Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 26 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 27 U.S. Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 28 Canada Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 29 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 30 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 31 Canada Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 32 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 33 Canada Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 34 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 35 Canada Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 36 Europe Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 37 Europe Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 38 Europe Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 39 Europe Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 40 Europe Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 41 Europe Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 42 Europe Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 43 Europe Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 44 Europe Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 45 UK Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 46 UK Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 47 UK Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 48 UK Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 49 UK Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 50 UK Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 51 UK Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 52 UK Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 53 Germany Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 54 Germany Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 55 Germany Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 56 Germany Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 57 Germany Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 58 Germany Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 59 Germany Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 60 Germany Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 61 France Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 62 France Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 63 France Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 64 France Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 65 France Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 66 France Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 67 France Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 68 France Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 69 Italy Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 70 Italy Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 71 Italy Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 72 Italy Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 73 Italy Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 74 Italy Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 75 Italy Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 76 Italy Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 77 Spain Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 78 Spain Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 79 Spain Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 80 Spain Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 81 Spain Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 82 Spain Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 83 Spain Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 84 Spain Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 85 Denmark Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 86 Denmark Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 87 Denmark Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 88 Denmark Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 89 Denmark Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 90 Denmark Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 91 Denmark Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 92 Denmark Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 93 Sweden Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 94 Sweden Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 95 Sweden Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 96 Sweden Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 97 Sweden Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 98 Sweden Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 99 Sweden Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 100 Sweden Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 101 Norway Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 102 Norway Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 103 Norway Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 104 Norway Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 105 Norway Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 106 Norway Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 107 Norway Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 108 Norway Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 109 Asia Pacific Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 110 Asia Pacific Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 111 Asia Pacific Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 112 Asia Pacific Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 113 Asia Pacific Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 114 Asia Pacific Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 115 Asia Pacific Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 116 Asia Pacific Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 117 Asia Pacific Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 118 Japan Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 119 Japan Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 120 Japan Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 121 Japan Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 122 Japan Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 123 Japan Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 124 Japan Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 125 Japan Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 126 China Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 127 China Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 128 China Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 129 China Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 130 China Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 China Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 132 China Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 133 China Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 134 India Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 135 India Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 136 India Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 137 India Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 138 India Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 139 India Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 140 India Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 141 India Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 142 South Korea Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 143 South Korea Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 144 South Korea Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 145 South Korea Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 146 South Korea Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 147 South Korea Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 148 South Korea Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 149 South Korea Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 150 Australia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 151 Australia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 152 Australia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 153 Australia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 154 Australia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 155 Australia Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 156 Australia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 157 Australia Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 158 Thailand Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 159 Thailand Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 160 Thailand Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 161 Thailand Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 162 Thailand Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 163 Thailand Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 164 Thailand Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 165 Thailand Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 166 Latin America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 167 Latin America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 168 Latin America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 169 Latin America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 170 Latin America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 171 Latin America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 172 Latin America Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 173 Latin America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 174 Latin America Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 175 Brazil Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 176 Brazil Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 177 Brazil Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 178 Brazil Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 179 Brazil Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 180 Brazil Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 181 Brazil Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 182 Brazil Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 183 Mexico Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 184 Mexico Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 185 Mexico Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 186 Mexico Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 187 Mexico Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 188 Mexico Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 189 Mexico Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 190 Mexico Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 191 Argentina Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 192 Argentina Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 193 Argentina Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 194 Argentina Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 195 Argentina Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 196 Argentina Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 197 Argentina Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 198 Argentina Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 199 Middle East & Africa Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 200 Middle East & Africa Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 201 Middle East & Africa Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 202 Middle East & Africa Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 203 Middle East & Africa Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 204 Middle East & Africa Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 205 Middle East & Africa Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 206 Middle East & Africa Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 207 Middle East & Africa Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 208 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 209 Saudi Arabia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 210 Saudi Arabia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 211 Saudi Arabia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 212 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 213 Saudi Arabia Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 214 Saudi Arabia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 215 Saudi Arabia Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 216 South Africa Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 217 South Africa Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 218 South Africa Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 219 South Africa Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 220 South Africa Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 221 South Africa Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 222 South Africa Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 223 South Africa Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 224 UAE Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 225 UAE Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 226 UAE Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 227 UAE Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 228 UAE Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 229 UAE Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 230 UAE Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 231 UAE Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)
  • Table 232 Kuwait Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 233 Kuwait Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 234 Kuwait Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 235 Kuwait Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 236 Kuwait Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 237 Kuwait Pharmaceutical Market, By Formulation, 2018 - 2030 (USD Billion)
  • Table 238 Kuwait Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 239 Kuwait Pharmaceutical Market, By End Market, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Pharmaceutical Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Pharmaceutical market: Molecule type outlook and key takeaways
  • Fig. 15 Pharmaceutical market: Molecule type movement analysis & market share 2022 & 2030
  • Fig. 16 Biologics & biosimilars (large molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 17 Conventional drugs (small molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 18 Pharmaceutical market: Product outlook and key takeaways
  • Fig. 19 Pharmaceutical market: Product movement analysis & market share 2022 & 2030
  • Fig. 20 Branded pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 21 Generics pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 22 Pharmaceutical market: Type outlook and key takeaways
  • Fig. 23 Pharmaceutical market: Type movement analysis & market share 2022 & 2030
  • Fig. 24 Prescription pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 25 OTC pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 26 Pharmaceutical market: Disease outlook and key takeaways
  • Fig. 27 Pharmaceutical market: Disease movement analysis & market share 2022 & 2030
  • Fig. 28 Cancer market, 2018 - 2030 (USD Billion)
  • Fig. 29 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
  • Fig. 30 Diabetes market, 2018 - 2030 (USD Billion)
  • Fig. 31 Infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig. 32 Neurological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 33 Respiratory diseases market, 2018 - 2030 (USD Billion)
  • Fig. 34 Autoimmune diseases market, 2018 - 2030 (USD Billion)
  • Fig. 35 Mental health disorders market, 2018 - 2030 (USD Billion)
  • Fig. 36 Gastrointestinal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 37 Women's health diseases market, 2018 - 2030 (USD Billion)
  • Fig. 38 Genetic and rare genetic diseases market, 2018 - 2030 (USD Billion)
  • Fig. 39 Dermatological conditions market, 2018 - 2030 (USD Billion)
  • Fig. 40 Obesity market, 2018 - 2030 (USD Billion)
  • Fig. 41 Renal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 42 Liver conditions market, 2018 - 2030 (USD Billion)
  • Fig. 43 Hemotological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 44 Eye conditions market, 2018 - 2030 (USD Billion)
  • Fig. 45 Infertility conditions market, 2018 - 2030 (USD Billion)
  • Fig. 46 Endocrine disorders market, 2018 - 2030 (USD Billion)
  • Fig. 47 Allergies market, 2018 - 2030 (USD Billion)
  • Fig. 48 Other diseases market, 2018 - 2030 (USD Billion)
  • Fig. 49 Pharmaceutical market: Route of administration outlook and key takeaways
  • Fig. 50 Pharmaceutical market: Route of administration movement analysis & market share 2022 & 2030
  • Fig. 51 Oral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 52 Topical pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 53 Parenteral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 54 Inhalations pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 55 Others pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 56 Pharmaceutical market: Formulation outlook and key takeaways
  • Fig. 57 Pharmaceutical market: Formulation movement analysis & market share 2022 & 2030
  • Fig. 58 Tablets pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 59 Capsules pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 60 Injectables pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 61 Sprays pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 62 Suspensions pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 63 Powders pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 64 Others formulation pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 65 Pharmaceutical market: Age group outlook and key takeaways
  • Fig. 66 Pharmaceutical market: Age group movement analysis & market share 2022 & 2030
  • Fig. 67 Children & Adolescents pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 68 Adults pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 69 Geriatric pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 70 Pharmaceutical market: End market outlook and key takeaways
  • Fig. 71 Pharmaceutical market: End movement analysis & market share 2022 & 2030
  • Fig. 72 Hospitals pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 73 Clinics pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 74 Others pharmaceutical market, 2018 - 2030 (USD Billion
  • Fig. 75 Regional Outlook, 2022 & 2030
  • Fig. 76 Regional Market Dashboard
  • Fig. 77 Regional Market Place: Key Takeaways
  • Fig. 78 North America, SWOT Analysis
  • Fig. 79 Europe, SWOT Analysis
  • Fig. 80 Asia Pacific, SWOT Analysis
  • Fig. 81 Latin America, SWOT Analysis
  • Fig. 82 MEA, SWOT Analysis
  • Fig. 83 North America
  • Fig. 84 North America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 U.S. Key Country Dynamics
  • Fig. 86 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Canada Key Country Dynamics
  • Fig. 88 Canada Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Europe
  • Fig. 90 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 UK Key Country Dynamics
  • Fig. 92 UK Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Germany Key Country Dynamics
  • Fig. 94 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 France Key Country Dynamics
  • Fig. 96 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Italy Key Country Dynamics
  • Fig. 98 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 99 Spain Key Country Dynamics
  • Fig. 100 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 101 Denmark Key Country Dynamics
  • Fig. 102 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 103 Sweden Key Country Dynamics
  • Fig. 104 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 105 Norway Key Country Dynamics
  • Fig. 106 Norway Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 107 Asia Pacific
  • Fig. 108 Asia - Pacific Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 109 Japan Key Country Dynamics
  • Fig. 110 Japan Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 111 China Key Country Dynamics
  • Fig. 112 China Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 113 India Key Country Dynamics
  • Fig. 114 India Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 115 Australia Key Country Dynamics
  • Fig. 116 Australia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 117 Thailand Key Country Dynamics
  • Fig. 118 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 119 South Korea Key Country Dynamics
  • Fig. 120 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 121 Latin America
  • Fig. 122 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 123 Brazil Key Country Dynamics
  • Fig. 124 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 125 Mexico Key Country Dynamics
  • Fig. 126 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 127 Argentina Key Country Dynamics
  • Fig. 128 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 129 MEA
  • Fig. 130 MEA Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 South Africa Key Country Dynamics
  • Fig. 132 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Saudi Arabia Key Country Dynamics
  • Fig. 134 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 135 UAE Key Country Dynamics
  • Fig. 136 UAE Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 137 Kuwait Key Country Dynamics
  • Fig. 138 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 139 Strategy Mapping